17 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
7 May 24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7:39am
of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19 pandemic on our business
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
s a nd profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate
8-K
EX-99.1
6eq zxrlg
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
qxu0py
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
9hf9s 3l75iyrnp5t
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.2
n4m9gp12sbwtm8y051
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
tu97qlkec 0p
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
e21nd52h 71qblsq
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-99.1
9e982w2
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
EX-99.1
cdp1fvuhvs4mqpyg9 c5
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
9lfr0wklf0
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
EX-99.1
18zf8iyf2d0 hpmy3ft
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
ez8l ly38jq4
11 May 22
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
EX-99.1
3iul7qgvqb3rora4
30 Mar 22
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides
7:29am
- Prev
- 1
- Next